510 related articles for article (PubMed ID: 36422515)
1. Optimizing the use of Paxlovid in clinical practice.
McCarthy MW
Drugs Today (Barc); 2022 Nov; 58(11):539-546. PubMed ID: 36422515
[TBL] [Abstract][Full Text] [Related]
2. Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs.
Saravolatz LD; Depcinski S; Sharma M
Clin Infect Dis; 2023 Jan; 76(1):165-171. PubMed ID: 35245942
[TBL] [Abstract][Full Text] [Related]
3. Preclinical discovery and development of nirmatrelvir/ritonavir combinational therapy for the treatment of COVID-19 and the lessons learned from SARS-COV-2 variants.
Pagliano P; Spera A; Sellitto C; Scarpati G; Folliero V; Piazza O; Franci G; Conti V; Ascione T
Expert Opin Drug Discov; 2023; 18(12):1301-1311. PubMed ID: 37614103
[TBL] [Abstract][Full Text] [Related]
4. Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
Hashemian SMR; Sheida A; Taghizadieh M; Memar MY; Hamblin MR; Bannazadeh Baghi H; Sadri Nahand J; Asemi Z; Mirzaei H
Biomed Pharmacother; 2023 Jun; 162():114367. PubMed ID: 37018987
[TBL] [Abstract][Full Text] [Related]
5. Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans.
Eng H; Dantonio AL; Kadar EP; Obach RS; Di L; Lin J; Patel NC; Boras B; Walker GS; Novak JJ; Kimoto E; Singh RSP; Kalgutkar AS
Drug Metab Dispos; 2022 May; 50(5):576-590. PubMed ID: 35153195
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of Paxlovid against COVID-19 is the result of the tight molecular docking between M
Dawood AA
Adv Med Sci; 2023 Mar; 68(1):1-9. PubMed ID: 36368287
[TBL] [Abstract][Full Text] [Related]
7. Genetic Surveillance of SARS-CoV-2 M
Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L
mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764
[TBL] [Abstract][Full Text] [Related]
8. Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment - California, December 2021-May 2022.
Malden DE; Hong V; Lewin BJ; Ackerson BK; Lipsitch M; Lewnard JA; Tartof SY
MMWR Morb Mortal Wkly Rep; 2022 Jun; 71(25):830-833. PubMed ID: 35737591
[TBL] [Abstract][Full Text] [Related]
9. Nirmatrelvir and ritonavir combination: an antiviral therapy for COVID-19.
Navitha Reddy G; Jogvanshi A; Naikwadi S; Sonti R
Expert Rev Anti Infect Ther; 2023; 21(9):943-955. PubMed ID: 37525997
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of Huashi Baidu granule plus Nirmatrelvir-Ritonavir combination therapy in patients with high-risk factors infected with Omicron (B.1.1.529): A multi-arm single-center, open-label, randomized controlled trial.
Yu Z; Zheng Y; Chen B; Lv J; Zhu X; Shang B; Xv Y; Tao R; Yang Y; Cong J; Li D; Wu H; Qv W; Zhang X; Xv C; Feng H; Yuan W; Gao Y
Phytomedicine; 2023 Nov; 120():155025. PubMed ID: 37639813
[TBL] [Abstract][Full Text] [Related]
11. Nirmatrelvir Plus Ritonavir: First Approval.
Lamb YN
Drugs; 2022 Apr; 82(5):585-591. PubMed ID: 35305258
[TBL] [Abstract][Full Text] [Related]
12. New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19.
Atmar RL; Finch N
Antimicrob Agents Chemother; 2022 Aug; 66(8):e0240421. PubMed ID: 35862759
[TBL] [Abstract][Full Text] [Related]
13. The effect of nirmatrelvir-ritonavir on viral clearance and length of hospital stay in patients infected with SARS-CoV-2 omicron variants.
Wang Y; Zhao D; Chen X; Liu X; Xiao W; Feng L
Influenza Other Respir Viruses; 2023 Feb; 17(2):e13095. PubMed ID: 36843224
[TBL] [Abstract][Full Text] [Related]
14. [Nirmatrelvir plus ritonavir (Paxlovid) a potent SARS-CoV-2 3CLpro protease inhibitor combination].
Reina J; Iglesias C
Rev Esp Quimioter; 2022 Jun; 35(3):236-240. PubMed ID: 35183067
[TBL] [Abstract][Full Text] [Related]
15. Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications.
Marzolini C; Kuritzkes DR; Marra F; Boyle A; Gibbons S; Flexner C; Pozniak A; Boffito M; Waters L; Burger D; Back DJ; Khoo S
Clin Pharmacol Ther; 2022 Dec; 112(6):1191-1200. PubMed ID: 35567754
[TBL] [Abstract][Full Text] [Related]
16. Advances and challenges in using nirmatrelvir and its derivatives against SARS-CoV-2 infection.
Chen W; Liang B; Wu X; Li L; Wang C; Xing D
J Pharm Anal; 2023 Mar; 13(3):255-261. PubMed ID: 36345404
[TBL] [Abstract][Full Text] [Related]
17. Paxlovid (Nirmatelvir/Ritonavir) and Tacrolimus Drug-Drug Interaction in a Kidney Transplant Patient with SARS-2-CoV infection: A Case Report.
Prikis M; Cameron A
Transplant Proc; 2022; 54(6):1557-1560. PubMed ID: 35599203
[TBL] [Abstract][Full Text] [Related]
18. Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients.
Parums DV
Med Sci Monit; 2022 Jan; 28():e935952. PubMed ID: 34972812
[TBL] [Abstract][Full Text] [Related]
19. Paxlovid: Mechanism of Action, Synthesis, and
Marzi M; Vakil MK; Bahmanyar M; Zarenezhad E
Biomed Res Int; 2022; 2022():7341493. PubMed ID: 35845944
[TBL] [Abstract][Full Text] [Related]
20. Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents.
Gentry CA; Nguyen P; Thind SK; Kurdgelashvili G; Williams RJ
J Infect; 2023 Mar; 86(3):248-255. PubMed ID: 36702309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
